Quarterly report · Q3
7446.TEDINET S100RLXQ
Period2022-10-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.9bn | 2022-10-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥37.3bn | 2021-10-01 → 2022-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.9bn | 2021-10-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥659m | 2022-10-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥763m | 2021-10-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥708m | 2022-10-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-10-01 → 2022-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥814m | 2021-10-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥707m | 2022-10-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥786m | 2021-10-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥499m | 2022-10-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥658m | 2021-10-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥539m | 2021-10-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥507m | 2022-10-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥559m | 2021-10-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥17.8bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥17.5bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥15.0bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.5bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥10.8bn | at 2022-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥7.2bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.6bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.4bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥553.84 | 2022-10-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥146.63 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥728.76 | 2021-10-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥596.99 | 2021-10-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥185.03 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.3% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.7% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.2% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-10-01 → 2023-06-30 | ¥313m |
| Otherother segments | revenue external | 2022-10-01 → 2023-06-30 | ¥313m |
| jpcrp040300-q3r_E02810-000Foodreportable segment | revenue | 2022-10-01 → 2023-06-30 | ¥2.5bn |
| jpcrp040300-q3r_E02810-000Foodreportable segment | revenue external | 2022-10-01 → 2023-06-30 | ¥2.5bn |
| jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segment | revenue | 2022-10-01 → 2023-06-30 | ¥13.5bn |
| jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segment | revenue external | 2022-10-01 → 2023-06-30 | ¥13.5bn |
| jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segment | revenue | 2022-10-01 → 2023-06-30 | ¥10.6bn |
| jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segment | revenue external | 2022-10-01 → 2023-06-30 | ¥10.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-10-01 → 2023-06-30 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-10-01 → 2023-06-30 | ¥26.9bn |
| Otherother segments | revenue | 2021-10-01 → 2022-06-30 | ¥318m |
| Otherother segments | revenue external | 2021-10-01 → 2022-06-30 | ¥318m |
| jpcrp040300-q3r_E02810-000Foodreportable segment | revenue | 2021-10-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q3r_E02810-000Foodreportable segment | revenue external | 2021-10-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segment | revenue | 2021-10-01 → 2022-06-30 | ¥13.8bn |
| jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segment | revenue external | 2021-10-01 → 2022-06-30 | ¥13.8bn |
| jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segment | revenue | 2021-10-01 → 2022-06-30 | ¥11.4bn |
| jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segment | revenue external | 2021-10-01 → 2022-06-30 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-10-01 → 2022-06-30 | ¥27.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-10-01 → 2022-06-30 | ¥27.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 382
| Item | Context | Value | Unit |
|---|---|---|---|
| Loss on retirement of noncurrent assets el | Prior1YTDDuration | 114000 | JPY |
| Loss on retirement of noncurrent assets el | CurrentYTDDuration | 197000 | JPY |
| Loss on valuation of investment securities el | Prior1YTDDuration | 29380000 | JPY |
| Loss on valuation of investment securities el | CurrentYTDDuration | － | JPY |
| Impairment loss el | Prior1YTDDuration | － | JPY |
| Impairment loss el | CurrentYTDDuration | 454000 | JPY |
| Loss on sales of golf club memberships el | Prior1YTDDuration | － | JPY |
| Loss on sales of golf club memberships el | CurrentYTDDuration | 300000 | JPY |
| Extraordinary loss | Prior1YTDDuration | 29494000 | JPY |
| Extraordinary loss | CurrentYTDDuration | 952000 | JPY |
| Income before income taxes | Prior1YTDDuration | 786372000 | JPY |
| Income before income taxes | CurrentYTDDuration | 706928000 | JPY |
| Income taxes current | Prior1YTDDuration | 212302000 | JPY |
| Income taxes current | CurrentYTDDuration | 181925000 | JPY |
| Income taxes deferred | Prior1YTDDuration | 15151000 | JPY |
| Income taxes deferred | CurrentYTDDuration | 18240000 | JPY |
| Income taxes | Prior1YTDDuration | 227454000 | JPY |
| Income taxes | CurrentYTDDuration | 200165000 | JPY |
| Profit loss | Prior1YTDDuration | 558917000 | JPY |
| Profit loss | CurrentYTDDuration | 506762000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YTDDuration | 19930000 | JPY |
| Profit loss attributable to non controlling interests | CurrentYTDDuration | 7738000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 538987000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 499023000 | JPY |
| Profit loss | Prior1YTDDuration | 558917000 | JPY |
| Profit loss | CurrentYTDDuration | 506762000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | -186713000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 149113000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | 683000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | 1276000 | JPY |
| Other comprehensive income | Prior1YTDDuration | -186029000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 150390000 | JPY |
| Comprehensive income | Prior1YTDDuration | 372887000 | JPY |
| Comprehensive income | CurrentYTDDuration | 657153000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 353084000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 649421000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 19802000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | 7731000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E02810-000PharmaceuticalProductsReportableSegmentsMember | 13757668000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E02810-000ReagentForClinicalTestReportableSegmentsMember | 11386330000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E02810-000FoodReportableSegmentsMember | 2439249000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OtherReportableSegmentsMember | 318445000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 27901693000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 27901693000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E02810-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E02810-000ReagentForClinicalTestReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E02810-000FoodReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_OtherReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |